To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

Inclusion Criteria:

• Diagnosis of RA (class I to III)
• Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

• Pregnant or breastfeeding
• Abnormal screening laboratory test values considered to be clinically significant